Drugs / Qingre Huatan Formula
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06857487 | Jun 2025 → Oct 2026 expected | ischemic stroke | Dongzhimen Hospital, Beijing | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qingre Huatan Formula | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06857487 ↗ |
| Known as | QHF | “Therefore, this study aims to determine whether Qingre Huatan Formula (QHF) initiated within 48 h of stroke onset prevents END in AIS patients compared with placebo.” PMID 42051694 ↗ Apr 2026 |
| Modality | Traditional medicine (herbal / TCM) | “This trial will provide valuable evidence for the efficacy and safety of traditional Chinese medicine for END in AIS patients.” PMID 42051694 ↗ Apr 2026 |
| Route | Oral | “Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.” NCT06857487 ↗ |